Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Treatment Efficacy and Safety Study of MYOBLOC in Treatment of Adult Upper Limb Spasticity and Open-Label Extension, Multiple-Treatment Safety Study of MYOBLOC

NCT04815967 is registered in ClinicalTrials.gov with Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC as lead sponsor.

NCT NCT04815967
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04815967 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Treatment Efficacy and Safety Study of MYOBLOC in Treatment of Adult Upper Limb Spasticity and Open-Label Extension, Multiple-Treatment Safety Study of MYOBLOC
Lead sponsor
Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC
Phase
Phase 2/3
Overall status
Terminated
Start date
November 2, 2021
Completion date
April 23, 2023
Enrollment
32 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

cerebral palsy, cerebrovascular accident, cervical spinal cord injury, multiple sclerosis, spasticity, traumatic brain injury